{"groups":[{"description":"Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1","id":"FG000","title":"Bortezomib and Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}